Nanobiosensing and Microfluidic Point-of-Care Testing, Key Laboratory of Luzhou, Department of Clinical Laboratory, The Affiliated Traditional Chinese Medicine Hospital,Southwest Medical University, Luzhou, 646000, PR China; Department of Laboratory Medicine, The People's Hospital of Chongging Liangjiang New Area, No. 199 Ren Xing Road, Yubei, Chongqing, 401121, PR China.
Nanobiosensing and Microfluidic Point-of-Care Testing, Key Laboratory of Luzhou, Department of Clinical Laboratory, The Affiliated Traditional Chinese Medicine Hospital,Southwest Medical University, Luzhou, 646000, PR China.
Talanta. 2024 Dec 1;280:126766. doi: 10.1016/j.talanta.2024.126766. Epub 2024 Aug 24.
Glypican-1 (GPC-1) protein-positive small extracellular vesicles (GPC-1-sEV) have been proposed as potential biomarkers for early diagnosis of pancreatic cancer. In this study, we present an integrated real-time isolation and detection platform (IRTIDP) to capture and analyze GPC-1-sEV directly from sera of pancreatic cancer patients. First, CD63 antibody-modified metal-organic framework (MOF) materials were utilized to enrich sEVs with a capture efficiency of 93.93 %. Second, a SERS probe was constructed by Raman reporter 4-MBA and GPC-1 antibody modified SERS active silver nanoparticles (AgNPs), which formed a sandwich complex structure of "MOFs@GPC-1-sEV@AgNPs-4-MBA" with MOFs-enriched sEVs. The IRTSDP can complete the capture and detection process within 35 min, with a detection limit for 1 GPC-1-sEV/μL, and linear range between 10∼10 GPC-1-sEV/mL. Furthermore, this approach has been applied to quantify serum sEV GPC-1 in clinical pancreatic cancer patients. Based on the SERS intensity analysis, pancreatic cancer patients can be distinguished from pancreatic cystadenoma patients and healthy individuals effectively using this innovative platform that provides highly specific and sensitive means for early diagnosis of pancreatic cancer as well as other tumor types.
磷脂酰聚糖蛋白-1（GPC-1）阳性的小细胞外囊泡（GPC-1-sEV）已被提议作为胰腺癌早期诊断的潜在生物标志物。在本研究中，我们提出了一种集成的实时分离和检测平台（IRTIDP），用于直接从胰腺癌患者的血清中捕获和分析 GPC-1-sEV。首先，使用 CD63 抗体修饰的金属有机骨架（MOF）材料来富集 sEV，其捕获效率为 93.93%。其次，通过拉曼报告分子 4-MBA 和 GPC-1 抗体修饰的 SERS 活性银纳米粒子（AgNPs）构建了 SERS 探针，形成了具有 MOF 富集 sEV 的“MOFs@GPC-1-sEV@AgNPs-4-MBA”三明治复合物结构。IRTSDp 可以在 35 分钟内完成捕获和检测过程，检测限为 1 GPC-1-sEV/μL，线性范围为 10∼10 GPC-1-sEV/mL。此外，该方法已应用于临床胰腺癌患者血清 sEV GPC-1 的定量。基于 SERS 强度分析，该创新平台能够有效地区分胰腺癌患者与胰腺囊腺瘤患者和健康个体，为胰腺癌和其他肿瘤类型的早期诊断提供了高度特异和敏感的手段。
